HEPA Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 1.95%

Insider Buying (Last 12 Months): $49,790.00

Insider Selling (Last 12 Months): $0.00

Hepion Pharmaceuticals Insider Trading History Chart

Hepion Pharmaceuticals Share Price & Price History

^$0.73

▼ -0.02 (-2.66%)

As of 09/12/2024 01:00 AM ET

Days: 30 | 90 | 365

Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳

From Mode Mobile | Ad

High-Growth Smartphone Startup 45 Million Users. $60M+ in Revenue. 32,481% Growth Rate. $1T+ market opportunity.

Claim Exclusive 100% Bonus: $0.25/Share

Hepion Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/27/2023	Peter Wijngaard	Director	Buy	2,500	$3.05	$7,625.00	9,501
11/24/2023	Peter Wijngaard	Director	Buy	2,500	$3.09	$7,725.00	7,001
9/19/2023	Peter Wijngaard	Director	Buy	1,000	$5.64	$5,640.00	4,501
9/18/2023	Robert T Foster	CEO	Buy	1,600	$5.60	$8,960.00	50,470
9/15/2023	Peter Wijngaard	Director	Buy	2,000	$5.60	$11,200.00	3,501
9/15/2023	Robert T Foster	CEO	Buy	1,600	$5.40	$8,640.00	48,870

The death of Nvidia?

From Porter & Company | Ad

Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.

So go here now to read my new report The Big AI Die-Up… while you still can.

SEC Filings (Institutional Ownership Changes) for Hepion Pharmaceuticals (NASDAQ:HEPA)

17.24% of Hepion Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Hepion Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/15/2024	Armistice Capital LLC	516,000	$0.53M	0.0%	+32.3%	9.428%
2/13/2024	Armistice Capital LLC	418,000	$1.35M	0.0%	+5.1%	9.631%
11/15/2023	Armistice Capital LLC	397,607	$1.98M	0.0%	N/A	10.360%
5/1/2023	Virtu Financial LLC	53,501	$42K	0.0%	+152.8%	0.070%
11/7/2022	Virtu Financial LLC	67,802	$34K	0.0%	+195.6%	0.089%
10/13/2022	PVG Asset Management Corp	107,915	$55K	0.2%	N/A	0.142%
8/12/2022	Ikarian Capital LLC	410,189	$0.24M	0.0%	-29.5%	0.538%
2/4/2022	Envestnet Asset Management Inc.	72,027	$82K	0.0%	+87.5%	0.094%
2/2/2022	PVG Asset Management Corp	100,089	$0.11M	0.4%	+92.5%	0.131%
11/10/2021	PVG Asset Management Corp	51,989	$80K	0.2%	-72.6%	0.068%
11/9/2021	BlackRock Inc.	1,634,012	$2.50M	0.0%	-1.0%	2.144%
11/5/2021	PNC Financial Services Group Inc.	39,034	$60K	0.0%	N/A	0.051%
10/13/2021	Asset Management Corp IL ADV	133,500	$0.20M	0.1%	+45.9%	0.175%
9/17/2021	Virtu Financial LLC	113,869	$0.23M	0.0%	-36.4%	0.149%
8/18/2021	Ikarian Capital LLC	1,365,059	$2.70M	0.2%	N/A	1.791%
8/17/2021	PVG Asset Management Corp	189,616	$0.38M	1.2%	+1,241.0%	0.249%
8/17/2021	Boothbay Fund Management LLC	155,069	$0.31M	0.0%	N/A	0.203%
8/16/2021	Morgan Stanley	91,106	$0.18M	0.0%	+197,956.5%	0.120%
8/16/2021	State Street Corp	322,716	$0.64M	0.0%	N/A	0.423%
8/16/2021	Goldman Sachs Group Inc.	68,399	$0.14M	0.0%	N/A	0.090%
8/13/2021	Altium Capital Management LP	446,000	$0.88M	0.2%	N/A	0.585%
8/13/2021	Geode Capital Management LLC	651,318	$1.29M	0.0%	+10.6%	0.854%
8/11/2021	BlackRock Inc.	1,649,929	$3.27M	0.0%	-3.9%	2.165%
8/6/2021	Asset Management Corp IL ADV	91,500	$0.18M	0.1%	N/A	0.120%
8/4/2021	Envestnet Asset Management Inc.	92,919	$0.18M	0.0%	+256.9%	0.122%
8/2/2021	Advisor Group Holdings Inc.	17,751	$35K	0.0%	+94.9%	0.023%
8/2/2021	McAdam LLC	55,978	$86K	0.0%	+52.8%	0.073%
5/19/2021	Virtu Financial LLC	179,030	$0.33M	0.0%	N/A	0.235%
5/14/2021	PVG Asset Management Corp	14,140	$26K	0.1%	N/A	0.019%
5/13/2021	Renaissance Technologies LLC	157,500	$0.29M	0.0%	-52.1%	0.207%
5/13/2021	Bank of New York Mellon Corp	48,602	$89K	0.0%	+18.7%	0.064%
5/12/2021	Northern Trust Corp	145,515	$0.27M	0.0%	+129.5%	0.191%
5/12/2021	Geode Capital Management LLC	588,718	$1.08M	0.0%	+190.6%	0.772%
5/12/2021	UBS Group AG	68,202	$0.13M	0.0%	+10,794.9%	0.089%
5/11/2021	Rockefeller Capital Management L.P.	20,000	$36K	0.0%	N/A	0.026%
5/10/2021	GSA Capital Partners LLP	160,775	$0.30M	0.0%	+80.5%	0.211%
5/7/2021	BlackRock Inc.	1,716,168	$3.16M	0.0%	+43.7%	2.251%
5/6/2021	Prospera Financial Services Inc	31,300	$58K	0.0%	-20.4%	0.041%
5/6/2021	Meitav Dash Investments Ltd.	44,000	$81K	0.0%	N/A	0.058%
5/4/2021	Envestnet Asset Management Inc.	26,037	$48K	0.0%	N/A	0.034%
4/28/2021	JGP Wealth Management LLC	15,000	$28K	0.0%	N/A	0.020%
4/26/2021	McAdam LLC	36,641	$67K	0.0%	N/A	0.048%
2/17/2021	Worth Venture Partners LLC	233,947	$0.51M	0.4%	N/A	2.592%
2/16/2021	Squarepoint Ops LLC	111,978	$0.25M	0.0%	+621.3%	1.241%
2/12/2021	Prospera Financial Services Inc	39,300	$86K	0.0%	N/A	0.435%
2/11/2021	Northern Trust Corp	63,402	$0.14M	0.0%	N/A	0.703%
2/10/2021	Renaissance Technologies LLC	329,022	$0.72M	0.0%	N/A	3.646%
2/9/2021	Perkins Capital Management Inc.	150,000	$0.33M	0.2%	N/A	1.662%
2/9/2021	Bank of New York Mellon Corp	40,945	$90K	0.0%	N/A	0.454%
2/5/2021	BlackRock Inc.	1,194,434	$2.62M	0.0%	+1,867.1%	13.235%
2/4/2021	GSA Capital Partners LLP	89,067	$0.20M	0.0%	N/A	0.987%
1/19/2021	Allen Capital Group LLC	23,685	$52K	0.0%	N/A	0.262%
11/16/2020	ExodusPoint Capital Management LP	11,632	$36K	0.0%	N/A	0.129%

Data available starting January 2016

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Today's Range

Now: $0.73

$0.70

$0.75

50 Day Range

MA: $0.80

$0.57

$1.07

52 Week Range

Now: $0.73

$0.55

$6.19

Volume

8,261 shs

Average Volume

95,006 shs

Market Capitalization

$4.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.85

Who are the company insiders with the largest holdings of Hepion Pharmaceuticals?: Hepion Pharmaceuticals' top insider shareholders include:
Robert T Foster (CEO)
Peter Wijngaard (Director)
Learn More about top insider investors at Hepion Pharmaceuticals.
Who are the major institutional investors of Hepion Pharmaceuticals?: Hepion Pharmaceuticals' top institutional investors include:
Armistice Capital LLC — 9.43%
Learn More about top institutional investors of Hepion Pharmaceuticals stock.
Which major investors are buying Hepion Pharmaceuticals stock?: Within the previous quarter, HEPA stock was bought by institutional investors including:
Armistice Capital LLC
During the previous year, these company insiders have bought Hepion Pharmaceuticals stock:
Robert T Foster (CEO)
Peter Wijngaard (Director)
Learn More investors buying Hepion Pharmaceuticals stock.